Metacrine Choosing Between Two NASH FXR Agonists It Calls Best-In-Class

By the end of the year, Metacrine, Inc. plans to select which of its two farnesoid X receptor (FXR) agonists in mid-stage development to move forward with in non-alcoholic steatohepatitis (NASH), and the firm believes whichever one it picks will offer a best-in-class profile based on the safety and efficacy data it has seen so far.

FXR agonists have been a popular class in NASH drug development, and the first drug to reach the US Food and Drug Administration for NASH – Intercept Pharmaceuticals, Inc.’s...